Article Text

Download PDFPDF
The need for personalised medicine for rheumatoid arthritis
  1. John D Isaacs1,
  2. Gianfranco Ferraccioli2
  1. 1Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University, Newcastle, UK
  2. 2Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
  1. Correspondence to Professor John D Isaacs, Institute of Cellular Medicine, Musculoskeletal Research Group, 4th Floor, Catherine Cookson Building, The Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; j.d.isaacs{at}


An expanding range of biological therapies is available for patients with rheumatoid arthritis. Clinical trials and real-life experience demonstrate significant interpatient heterogeneity in efficacy as well as important adverse effects of these treatments. In order to maximise their benefit:risk ratios and to minimise later joint damage, we need to define predictors of response and, ideally, of adverse effects for each of these drugs. There is huge interest in this field of ‘personalised medicine’, which should allow us to optimally match patient with treatment, providing the parallel benefit of reduced treatment costs. In this short article the current state of the art for licensed biological therapies is summarised. There have been some noteworthy discoveries but the challenge is now to design studies to confirm and validate these findings while also devising large, potentially international, collaborations to identify additional, robust biomarkers that predict outcome.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests JDI has consulted for Hoffman La Roche and Bristol-Myers Squibb, and received educational or research grants from Centocor, Wyeth and Abbott pharmaceuticals. GFF received fees for lectures from Roche, Abbott, Wyeth, Shering Plough and grant for research support from Wyeth, BMS and Roche

  • Provenence and peer review Not commissioned; externally peer reviewed.